Acasti Pharma Inc. (NASDAQ: ACST) (TSX-V: ACST) stock plunged more than 22% in the premarketing today after the news that, since obtaining a subpoena from IIROC Company needs to clarify that it’s management and Board of Directors are unsure of any radical change in the company’s activities that will account for the sudden uptick in market activity.
The company has a monthly performance of 87.40%, compared to its half year performance of -28.09%. The biotech firm has 32 employees on its payroll and a Market capitalization of 41.66M. The price of the stock was trading -25.16% away from its 200-day simple moving average.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
